Literature DB >> 26309898

Signaling mechanisms coupled to CXCL12/CXCR4-mediated cellular proliferation are PTEN-dependent.

Lesa A Begley1, Sathish Kasina2, Rajal B Shah3, Jill A Macoska4.   

Abstract

A key difference between normal and malignant prostate cells in vitro and in vivo is that both alleles of PTEN are largely intact in normal benign prostate glands and cultured epithelial cells, whereas one or both alleles of PTEN are mutant or deleted in the majority of prostate tumors and malignant prostate cancer cell lines. Intact PTEN suppresses phosphorylation of Akt downstream of PI3K activation in non-transformed cells whereas Akt phosphorylation is unimpeded in malignant cells that are often PTEN-deficient. We have previously shown that activation of the CXCL12/CXCR4 axis transactivates the EGFR to promote pro-proliferative signaling preferentially through the Raf/MEK/Erk pathway in benign prostate epithelial cells. These cells demonstrate little basal pAkt and these levels do not increase with CXCL12 stimulation because PTEN is intact and fully functional. Thus, inactivation of PTEN may be the critical factor that modulates downstream signaling and the specific CXCL12-stimulated proliferative responses of non-transformed and transformed prostate epithelial cells. Based on these data, we hypothesize that the CXCL12/CXCR4-mediated activation of downstream pro-proliferative signaling through the Raf/MEK/Erk or PI3K/Akt pathways is modulated by PTEN status.

Entities:  

Keywords:  BPH; CXCL12; CXCR4; PTEN; Prostate

Year:  2015        PMID: 26309898      PMCID: PMC4539110     

Source DB:  PubMed          Journal:  Am J Clin Exp Urol        ISSN: 2330-1910


  20 in total

1.  CXCL12 activates a robust transcriptional response in human prostate epithelial cells.

Authors:  Lesa A Begley; James W MacDonald; Mark L Day; Jill A Macoska
Journal:  J Biol Chem       Date:  2007-07-12       Impact factor: 5.157

2.  Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF.

Authors:  Soha Salama El Sheikh; Jan Domin; Paul Abel; Gordon Stamp; El-Nasir Lalani
Journal:  Neoplasia       Date:  2004 Nov-Dec       Impact factor: 5.715

3.  Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias.

Authors:  Maisa Yoshimoto; Jean-Claude Cutz; Paulo A S Nuin; Anthony M Joshua; Jane Bayani; Andrew J Evans; Maria Zielenska; Jeremy A Squire
Journal:  Cancer Genet Cytogenet       Date:  2006-09

4.  Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.

Authors:  C M Canil; M J Moore; E Winquist; T Baetz; M Pollak; K N Chi; S Berry; D S Ernst; L Douglas; M Brundage; B Fisher; A McKenna; L Seymour
Journal:  J Clin Oncol       Date:  2005-01-20       Impact factor: 44.544

5.  Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18.

Authors:  D Bello; M M Webber; H K Kleinman; D D Wartinger; J S Rhim
Journal:  Carcinogenesis       Date:  1997-06       Impact factor: 4.944

6.  Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.

Authors:  Shazli N Malik; Michael Brattain; Paramita M Ghosh; Dean A Troyer; Thomas Prihoda; Roble Bedolla; Jeffrey I Kreisberg
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

7.  Unexpected low-dose toxicity of the universal solvent DMSO.

Authors:  Joana Galvao; Benjamin Davis; Mark Tilley; Eduardo Normando; Michael R Duchen; M Francesca Cordeiro
Journal:  FASEB J       Date:  2013-12-10       Impact factor: 5.191

8.  The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy.

Authors:  L A Begley; S Kasina; J MacDonald; J A Macoska
Journal:  Cytokine       Date:  2008-06-24       Impact factor: 3.861

9.  Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer.

Authors:  Jeffrey I Kreisberg; Shazli N Malik; Thomas J Prihoda; Roble G Bedolla; Dean A Troyer; Suzanne Kreisberg; Paramita M Ghosh
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

10.  Frequent inactivation of PTEN in prostate cancer cell lines and xenografts.

Authors:  R J Vlietstra; D C van Alewijk; K G Hermans; G J van Steenbrugge; J Trapman
Journal:  Cancer Res       Date:  1998-07-01       Impact factor: 12.701

View more
  10 in total

1.  Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.

Authors:  Miodrag Dragoj; Jasna Bankovic; Evangelia Sereti; Sofija Jovanovic Stojanov; Konstantinos Dimas; Milica Pesic; Tijana Stankovic
Journal:  Invest New Drugs       Date:  2017-07-22       Impact factor: 3.850

2.  The clinicopathological and prognostic value of CXCR4 expression in patients with lung cancer: a meta-analysis.

Authors:  Liping Qiu; Yuanyuan Xu; Hui Xu; Biyun Yu
Journal:  BMC Cancer       Date:  2022-06-21       Impact factor: 4.638

3.  Interaction between CXCR4 and EGFR and downstream PI3K/AKT pathway in lung adenocarcinoma A549 cells and transplanted tumor in nude mice.

Authors:  Juan Wu; Ying Liu; Yaling Ma; Rui Wang; Xiaokun Ji; Yan Zhang; Yun Du
Journal:  Int J Clin Exp Pathol       Date:  2020-02-01

Review 4.  Post-Translational Modifications That Drive Prostate Cancer Progression.

Authors:  Ivana Samaržija
Journal:  Biomolecules       Date:  2021-02-09

5.  Association of rs1801157 single nucleotide polymorphism of CXCL12 gene in breast cancer in Pakistan and in-silico expression analysis of CXCL12-CXCR4 associated biological regulatory network.

Authors:  Samra Khalid; Rumeza Hanif
Journal:  PeerJ       Date:  2017-09-15       Impact factor: 2.984

6.  Mechanistic Insights into the Anti-angiogenic Activity of Trypanosoma cruzi Protein 21 and its Potential Impact on the Onset of Chagasic Cardiomyopathy.

Authors:  Samuel Cota Teixeira; Daiana Silva Lopes; Sarah Natalie Cirilo Gimenes; Thaise Lara Teixeira; Marcelo Santos da Silva; Rebecca Tavares E Silva Brígido; Felipe Andrés Cordero da Luz; Aline Alves da Silva; Makswell Almeida Silva; Pilar Veras Florentino; Paula Cristina Brígido Tavares; Marlus Alves Dos Santos; Veridiana de Melo Rodrigues Ávila; Marcelo José Barbosa Silva; Maria Carolina Elias; Renato Arruda Mortara; Claudio Vieira da Silva
Journal:  Sci Rep       Date:  2017-03-21       Impact factor: 4.379

7.  C-C motif ligand 5 promotes migration of prostate cancer cells in the prostate cancer bone metastasis microenvironment.

Authors:  Satoko Urata; Kouji Izumi; Kaoru Hiratsuka; Aerken Maolake; Ariunbold Natsagdorj; Kazuyoshi Shigehara; Hiroaki Iwamoto; Suguru Kadomoto; Tomoyuki Makino; Renato Naito; Yoshifumi Kadono; Wen-Jye Lin; Guzailinuer Wufuer; Kazutaka Narimoto; Atsushi Mizokami
Journal:  Cancer Sci       Date:  2018-02-14       Impact factor: 6.716

Review 8.  Thromboinflammatory Processes at the Nexus of Metabolic Dysfunction and Prostate Cancer: The Emerging Role of Periprostatic Adipose Tissue.

Authors:  Ibrahim AlZaim; Aya Al-Saidi; Safaa H Hammoud; Nadine Darwiche; Yusra Al-Dhaheri; Ali H Eid; Ahmed F El-Yazbi
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

9.  Donor bone-marrow CXCR4+ Foxp3+ T-regulatory cells are essential for costimulation blockade-induced long-term survival of murine limb transplants.

Authors:  Liqing Wang; Zhonglin Wang; Rongxiang Han; Arabinda Samanta; Guanghui Ge; L Scott Levin; Matthew H Levine; Wayne W Hancock
Journal:  Sci Rep       Date:  2020-06-09       Impact factor: 4.379

10.  Double-Targeted Knockdown of miR-21 and CXCR4 Inhibits Malignant Glioma Progression by Suppression of the PI3K/AKT and Raf/MEK/ERK Pathways.

Authors:  Feijiao Liu; Bo Yang
Journal:  Biomed Res Int       Date:  2020-10-15       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.